---
title: "Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286649732.md"
description: "Acrivon Pharmaceuticals received a Buy rating from analyst Michael Okunewitch of Maxim Group, with a price target of $7.00. The rating is supported by the company's strong cash position of nearly $100M and promising clinical data for ACR-368 in treating recurrent high-grade endometrial cancer. The company is also diversifying its pipeline with new therapies showing early positive results."
datetime: "2026-05-16T15:55:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286649732.md)
  - [en](https://longbridge.com/en/news/286649732.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286649732.md)
---

# Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy

Acrivon Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $7.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Michael Okunewitch has given his Buy rating due to a combination of factors, including Acrivon’s solid financial runway and encouraging clinical progress with its lead asset, ACR-368. The company ended 1Q26 with close to $100M in cash and investments, which he views as sufficient to fund upcoming value-creating milestones, particularly the continued advancement of the potentially registrational Phase 2 program.

He also highlights robust emerging efficacy data for ACR-368 in recurrent high-grade endometrial cancer, with notable response rates in both biomarker-selected and all-comer serous populations, supporting a broad development strategy. Additional upside stems from pipeline diversification, including a dual WEE1/PKMYT1 inhibitor showing early tumor shrinkage with a favorable safety profile, and a differentiated CDK11 program that could validate the AP3 platform and tap into a high-interest AML market.

### Related Stocks

- [ACRV.US](https://longbridge.com/en/quote/ACRV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)